Treatment of metastatic urachal carcinoma in an elderly woman

Nature Clinical Practice Oncology

Volumn 5, Issue 1, 2008, Pages 55-58

  Mohile, Supriya G ^a   Schleicher, Lori ^b   Petrylak, Daniel P ^b  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN 20; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; IFL PROTOCOL; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; AGED; BLADDER CARCINOMA; CASE REPORT; COMPRESSION FRACTURE; COMPUTER ASSISTED TOMOGRAPHY; CYSTECTOMY; CYSTOSCOPY; DIARRHEA; DRUG DOSE REDUCTION; DYSURIA; FEMALE; FOLLOW UP; HEMATURIA; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; ISCHIALGIA; LYMPH NODE DISSECTION; METASTASIS; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PELVIS LYMPH NODE; PELVIS TUMOR; PHYSICAL EXAMINATION; PRIORITY JOURNAL; REVIEW; SMOKING; TUMOR RECURRENCE; URACHUS; URACHUS CARCINOMA; URINALYSIS; VERTEBRA FRACTURE; ADJUVANT THERAPY; ARTICLE; BLADDER TUMOR; DIFFERENTIAL DIAGNOSIS; LYMPHADENECTOMY; MULTIMODALITY CANCER THERAPY; SIGNET RING CARCINOMA;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA, SIGNET RING CELL; COMBINED MODALITY THERAPY; CYSTECTOMY; DIAGNOSIS, DIFFERENTIAL; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; LYMPH NODE EXCISION; NEOPLASM RECURRENCE, LOCAL; PELVIC NEOPLASMS; RADIOTHERAPY, ADJUVANT; URACHUS; URINARY BLADDER NEOPLASMS;

EID: 38449102460     PISSN: 17434254     EISSN: 17434262     Source Type: Journal    
DOI: 10.1038/ncponc1009     Document Type: Review

References (17)

1. Wright JL et al. (2006) Differences in survival among patients with urachal and nonurachal adenocarcinomas of the bladder. Cancer 107: 721-728
2. Sheldon CA et al. (1984) Malignant urachal lesions. J Urol 131: 1-8
3. Siefker-Radtke A (2006) Urachal carcinoma: Surgical and chemotherapeutic options. Expert Rev Anticancer Ther 6: 1715-1721
4. Ashley RA et al. (2006) Urachal carcinoma: Clinicopathologic features and long-term outcomes of an aggressive malignancy. Cancer 107: 712-720
5. Pinthus JH et al. (2006) Population based survival data on urachal tumors. J Urol 175: 2042-2047
6. Siefker-Radtke A et al. (2003) Multimodality management of urachal carcinoma: The MD Anderson Cancer Center experience. J Urol 169 1295-1298
7. Herr HW et al. (1997) Urachal carcinoma: Contemporary surgical outcomes. J Urol 178: 74-78
8. Herr HW (1994) Urachal carcinoma: The case for extended partial cystectomy. J Urol 151: 365-366
9. Kawakami S et al. (2001) Successful treatment of metastatic adenocarcinoma of the urachus: Report of 2 cases with more than 10-year survival. Urology 58: 462
10. Logothetis CJ et al. (1985) Chemotherapy for adenocarcinomas of bladder and urachal origin: 5-fluorouracil, doxorubicin, and mitomycin-C. Urology 26: 252-255
11. Ichiyanagi O et al. (1998) Successful chemotherapy in a patient with recurrent carcinoma of the urachus. Int Urol Nephrol 30 569-573
12. Quilty PM (1987) Urachal carcinoma: A response to chemotherapy. Br J Urol 60: 372
13. Rothenberg ML et al. (1993) Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol 11: 2194-2204
14. Hurwitz HI et al. (2005) Bevacizumab in combination with fluorouracil and leucovorin: An active regimen for first-line metastatic colorectal cancer. J Clin Oncol 23: 3502-3508
15. Pozzo C et al. (2004) Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: Results of a randomized phase II study. Ann Oncol 15: 1773-1781
16. Bouche O et al. (2004) Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: A Federation Francophone de Cancerologie Digestive Group Study - FFCD 9803. J Clin Oncol 22 4319-4328
17. Kume H et al. (2006) Irinotecan as a new agent for urachal cancer. Urol Int 76: 281-282